Fig. 1 · Structure

Documents & Downloads

NS 309

Cat. No. A11934 CAS 18711-16-5

KCa3.1 channel activator

NS 309 is a positive modulator of small- and intermediate- conductance Ca2+-activated K+ channels (KCa2 and KCa3.1 channels).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

NS 309 Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of NS 309 from 2 published references. In vitro models include CA1 neurons from 17- to 21-day-old mice.

NS 309 In Vitro Studies

Mouse CA1 neurons received bath application of 50 μM NS 309 in a design involving a depolarization step. IAHP increased in all tested cells compared with before application. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

IAHP response in mouse CA1 neurons

Cell-based study · CA1 neurons from 17- to 21-day-old mice [1]

CA1 neurons from mice received bath application of 50 μM NS 309 in a design using a depolarization step. Compared with before application, NS 309 increased IAHP in all cells tested.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IAHPIAHP six of six cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM
Method
bath
Co-treatment
Other interventions in this design: depolarization step. Compound effect isolated by the comparison: Before NS309 application.
Reported limits
Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: NS 309

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Activation of KCa2 channels prevents the increases in [Ca2+]i after glutamate exposure in neurons (S16, S17, S18, S19)

IAHP: IAHP; comparator: Before NS309 application — Results > Activation of KCa2 channels prevents the increases in [Ca2+]i after glutamate exposure in neurons (S16, S18)

NS 309 In Vivo Studies

In adult New Zealand white rabbits with SCI/R, a design comparing 2 mg/kg NS 309 with vehicle found no significant differences in blood pH, PaO2, PaCO2, or glucose among all groups. Following intraperitoneal administration of 2 mg/kg NS 309 at spinal cord ischemia initiation, the NS 309 group had more normal motor neurons than the vehicle group at 72 h after reperfusion. [2]

Blood measurements in rabbits with SCI/R

Animal study · Adult New Zealand white rabbits (2.5–3.0 kg); SCI/R [2]

Adult New Zealand white rabbits with SCI/R received NS 309 at 2 mg/kg or vehicle. No significant differences in blood pH, PaO2, PaCO2, or glucose were observed among all groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PaO2; 10 min after ischemia; 10 min after reperfusionPaO2 127.9 ± 15.2 mm Hg; 131.6 ± 12.3 mm Hg[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
NS 309 2 mg/kgVehicle127.9 ± 15.2 mm Hg; 131.6 ± 12.3 mm Hg; no significant differences in blood pH, PaO2, PaCO2, or glucose were observed among all groups[2]
NS 309 2 mg/kg
Model: Adult New Zealand white rabbits (2.5–3.0 kg); SCI/R
Reported limits: Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: NS 309

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals and Agents (S1); Materials and Methods > SCI/R Model (S7, S10); Results > SCI/R Decreases the Expression of SK/KCa1 Subtype (S59, S60); Table 2 (T2.h1, T2.r4, T2.r5, T2.r6, T2.r7, T2.r8, T2.r9)

PaO2; 10 min after ischemia; 10 min after reperfusion: PaO2; 10 min after ischemia; 10 min after reperfusion; comparator: Vehicle — Results > SCI/R Decreases the Expression of SK/KCa1 Subtype (S60); Table 2 (T2.h1, T2.r4, T2.r6, T2.r7, T2.r9)

NS 309 2 mg/kg · Results > SCI/R Decreases the Expression of SK/KCa1 Subtype (S59, S60); Table 2 (T2.h1, T2.r6, T2.r9)

Normal motor neurons after spinal cord ischemia and reperfusion

Animal study · Adult New Zealand white rabbits (2.5–3.0 kg); SCI/R; n = 8 [2]

Adult New Zealand white rabbits with SCI/R received 2 mg/kg NS 309 by intraperitoneal injection at spinal cord ischemia initiation. At 72 h after reperfusion, the NS 309 group had more normal motor neurons than the vehicle group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of normal motor neurons; at 72 h after reperfusionReported result The number of normal motor neurons in NS309 group was higher than that in vehicle group[2]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
at the time of spinal cord ischemia initiation
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
NS 309 2 mg/kgsaline (0.9%) with 1% DMSOThe number of normal motor neurons in NS309 group was higher than that in vehicle group[2]
NS 309 2 mg/kg
Model: Adult New Zealand white rabbits (2.5–3.0 kg); SCI/R; n = 8
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: NS 309

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals and Agents (S1); Materials and Methods > SCI/R Model (S7, S10); Materials and Methods > Experimental Design > Experimental 2 (S17, S18); Results > The SK/KCa Channel Activator NS309 Protects Against SCI/R (S69); FIGURE 2 legend (S104, S108)

number of normal motor neurons; at 72 h after reperfusion: number of normal motor neurons; at 72 h after reperfusion; comparator: saline (0.9%) with 1% DMSO — Results > The SK/KCa Channel Activator NS309 Protects Against SCI/R (S69); FIGURE 2 legend (S104)

NS 309 2 mg/kg · Materials and Methods > Experimental Design > Experimental 2 (S18); Results > The SK/KCa Channel Activator NS309 Protects Against SCI/R (S69)

Specifications

Manufacturer Adooq Bioscience
Actions Modulator, Activator
CAS Number 18711-16-5
Applications KCa3.1 channel activator
Formula C8H4Cl2N2O2
Molecular Weight 231
SMILES
C1=CC(=C(C2=NC(=O)C(=C21)NO)Cl)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

NS 309 Research References

  1. [1] Dolga AM, Terpolilli N, Kepura F, et al. KCa2 channels activation prevents [Ca2+]i deregulation and reduces neuronal death following glutamate toxicity and cerebral ischemia. Cell Death Dis (2011). PMID: 21509037 DOI: 10.1038/cddis.2011.30 Source material
  2. [2] Zhu J, Yang LK, Chen WL, et al. Activation of SK/KCa Channel Attenuates Spinal Cord Ischemia-Reperfusion Injury via Anti-oxidative Activity and Inhibition of Mitochondrial Dysfunction in Rabbits. Front Pharmacol (2019). PMID: 31001121 DOI: 10.3389/fphar.2019.00325 Source material

Added to your cart

View Cart Checkout
Loading...